{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T01:32:20Z","timestamp":1769045540408,"version":"3.49.0"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004167","name":"Medicines for Malaria Venture","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004167","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002992","name":"Department for International Development, UK Government","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002992","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007843","name":"Norwegian Agency for Development Cooperation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007843","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009099","name":"Irish Aid","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009099","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009022","name":"Newcrest Mining","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009022","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,3,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Interventions that effectively target Plasmodium vivax are critical for the future control and elimination of malaria. We conducted a P. vivax volunteer infection study to characterize the antimalarial activity of artefenomel, a new drug candidate.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Eight healthy, malaria-naive participants were intravenously inoculated with blood-stage P. vivax and subsequently received a single oral 200-mg dose of artefenomel. Blood samples were collected to monitor the development and clearance of parasitemia, and plasma artefenomel concentration. Mosquito feeding assays were conducted before artefenomel dosing to investigate parasite transmissibility.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Initial parasite clearance occurred in all participants after artefenomel administration (log10 parasite reduction ratio over 48 hours, 1.67; parasite clearance half-life, 8.67 hours). Recrudescence occurred in 7 participants 11\u201314 days after dosing. A minimum inhibitory concentration of 0.62 ng\/mL and minimum parasiticidal concentration that achieves 90% of maximum effect of 0.83 ng\/mL were estimated, and a single 300-mg dose was predicted to clear 109 parasites per milliliter with 95% certainty. Gametocytemia developed in all participants and was cleared 4\u20138 days after dosing. At peak gametocytemia, 75% of participants were infectious to mosquitoes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The in vivo antimalarial activity of artefenomel supports its further clinical development as a treatment for P. vivax malaria.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Clinical Trials Registration<\/jats:title>\n                  <jats:p>NCT02573857.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/infdis\/jiaa287","type":"journal-article","created":{"date-parts":[[2020,5,26]],"date-time":"2020-05-26T19:10:13Z","timestamp":1590520213000},"page":"1062-1069","source":"Crossref","is-referenced-by-count":11,"title":["Antimalarial Activity of Artefenomel Against Asexual Parasites and Transmissible Gametocytes During Experimental Blood-Stage <i>Plasmodium vivax<\/i> Infection"],"prefix":"10.1093","volume":"225","author":[{"given":"Katharine A","family":"Collins","sequence":"first","affiliation":[{"name":"QIMR Berghofer Medical Research Institute, Herston Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Azrin N","family":"Abd-Rahman","sequence":"additional","affiliation":[{"name":"QIMR Berghofer Medical Research Institute, Herston Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louise","family":"Marquart","sequence":"additional","affiliation":[{"name":"QIMR Berghofer Medical Research Institute, Herston Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emma","family":"Ballard","sequence":"additional","affiliation":[{"name":"QIMR Berghofer Medical Research Institute, Herston Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathalie","family":"Gobeau","sequence":"additional","affiliation":[{"name":"Medicine for Malaria Venture, Meyrin, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Griffin","sequence":"additional","affiliation":[{"name":"QIMR Berghofer Medical Research Institute, Herston Australia"},{"name":"The University of Queensland, Brisbane, Australia"},{"name":"Department of Medicine and Infectious Diseases, Mater Hospital and Mater Research, South Brisbane, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephan","family":"Chalon","sequence":"additional","affiliation":[{"name":"Medicine for Malaria Venture, Meyrin, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0769-9649","authenticated-orcid":false,"given":"J\u00f6rg J","family":"M\u00f6hrle","sequence":"additional","affiliation":[{"name":"Medicine for Malaria Venture, Meyrin, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James S","family":"McCarthy","sequence":"additional","affiliation":[{"name":"QIMR Berghofer Medical Research Institute, Herston Australia"},{"name":"The University of Queensland, Brisbane, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,6,1]]},"reference":[{"key":"2022031508220895300_CIT0001","doi-asserted-by":"crossref","DOI":"10.30875\/7e6f8c91-en","volume-title":"World malaria report 2019","author":"World Health Organization","year":"2019"},{"key":"2022031508220895300_CIT0002","doi-asserted-by":"crossref","first-page":"15","DOI":"10.4269\/ajtmh.16-0141","article-title":"Global epidemiology of Plasmodium vivax","volume":"95","author":"Howes","year":"2016","journal-title":"Am J Trop Med Hyg"},{"key":"2022031508220895300_CIT0003","doi-asserted-by":"crossref","first-page":"79","DOI":"10.4269\/ajtmh.2007.77.79","article-title":"Vivax malaria: neglected and not benign","volume":"77","author":"Price","year":"2007","journal-title":"Am J Trop Med Hyg"},{"key":"2022031508220895300_CIT0004","doi-asserted-by":"crossref","first-page":"62","DOI":"10.4269\/ajtmh.16-0180","article-title":"Key knowledge gaps for Plasmodium vivax control and elimination","volume":"95","author":"Bassat","year":"2016","journal-title":"Am J Trop Med Hyg"},{"key":"2022031508220895300_CIT0005","doi-asserted-by":"crossref","first-page":"121","DOI":"10.4269\/ajtmh.1963.12.121","article-title":"Pitfalls in a discovery: the chronicle of chloroquine","volume":"12","author":"Coatney","year":"1963","journal-title":"Am J Trop Med Hyg"},{"key":"2022031508220895300_CIT0006","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/S1473-3099(14)70855-2","article-title":"Global extent of chloroquine-resistant Plasmodium vivax: a systematic review and meta-analysis","volume":"14","author":"Price","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"2022031508220895300_CIT0007","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4269\/ajtmh.16-0517","article-title":"Attacking Plasmodium vivax","volume":"95","author":"Baird","year":"2016","journal-title":"Am J Trop Med Hyg"},{"key":"2022031508220895300_CIT0008","volume-title":"Artemesinin and aretemisinin-based combination therapy resistance: status report 2016","author":"World Health Organization","year":"2016"},{"key":"2022031508220895300_CIT0009","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1097\/QCO.0000000000000574","article-title":"Tafenoquine: the new kid on the block","volume":"32","author":"Chen","year":"2019","journal-title":"Curr Opin Infect Dis"},{"key":"2022031508220895300_CIT0010","doi-asserted-by":"crossref","first-page":"17050","DOI":"10.1038\/nrdp.2017.50","article-title":"Malaria","volume":"3","author":"Phillips","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"2022031508220895300_CIT0011","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S1473-3099(17)30171-8","article-title":"Safety, tolerability, pharmacokinetics, and activity of the novel long-acting antimalarial DSM265: a two-part first-in-human phase 1a\/1b randomised study","volume":"17","author":"McCarthy","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"2022031508220895300_CIT0012","doi-asserted-by":"crossref","first-page":"e0005139","DOI":"10.1371\/journal.pntd.0005139","article-title":"Safety and reproducibility of a clinical trial system using induced blood stage Plasmodium vivax infection and its potential as a model to evaluate malaria transmission","volume":"10","author":"Griffin","year":"2016","journal-title":"PLoS Negl Trop Dis"},{"key":"2022031508220895300_CIT0013","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1093\/infdis\/jit394","article-title":"Experimentally induced blood-stage Plasmodium vivax infection in healthy volunteers","volume":"208","author":"McCarthy","year":"2013","journal-title":"J Infect Dis"},{"key":"2022031508220895300_CIT0014","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1172\/JCI134923","article-title":"A Plasmodium vivax experimental human infection model for evaluating efficacy of interventions","volume":"130:","author":"Collins","year":"2020","journal-title":"J Clin Invest"},{"key":"2022031508220895300_CIT0015","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1128\/mr.60.2.301-315.1996","article-title":"Artemisinin and the antimalarial endoperoxides: from herbal remedy to targeted chemotherapy","volume":"60","author":"Meshnick","year":"1996","journal-title":"Microbiol Rev"},{"key":"2022031508220895300_CIT0016","doi-asserted-by":"crossref","first-page":"4400","DOI":"10.1073\/pnas.1015762108","article-title":"Synthetic ozonide drug candidate OZ439 offers new hope for a single-dose cure of uncomplicated malaria","volume":"108","author":"Charman","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022031508220895300_CIT0017","doi-asserted-by":"crossref","first-page":"5258","DOI":"10.1128\/AAC.00283-12","article-title":"Comparative ex vivo activity of novel endoperoxides in multidrug-resistant Plasmodium falciparum and P. vivax","volume":"56","author":"Marfurt","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2022031508220895300_CIT0018","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1093\/jac\/dkw174","article-title":"Efficacy of OZ439 (artefenomel) against early Plasmodium falciparum blood-stage malaria infection in healthy volunteers","volume":"71","author":"McCarthy","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"2022031508220895300_CIT0019","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/j.1365-2125.2012.04368.x","article-title":"First-in-man safety and pharmacokinetics of synthetic ozonide OZ439 demonstrates an improved exposure profile relative to other peroxide antimalarials","volume":"75","author":"Moehrle","year":"2013","journal-title":"Br J Clin Pharmacol"},{"key":"2022031508220895300_CIT0020","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S1473-3099(15)00320-5","article-title":"Antimalarial activity of artefenomel (OZ439), a novel synthetic antimalarial endoperoxide, in patients with Plasmodium falciparum and Plasmodium vivax malaria: an open-label phase 2 trial","volume":"16","author":"Phyo","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"2022031508220895300_CIT0021","article-title":"DSM265 at 400 milligrams clears asexual stage parasites but not mature gametocytes from the blood of healthy subjects experimentally infected with Plasmodium falciparum","volume":"63:e01837\u201318","author":"Collins","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2022031508220895300_CIT0022","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1186\/1475-2875-13-319","article-title":"Comparison of three methods for detection of gametocytes in Melanesian children treated for uncomplicated malaria","volume":"13","author":"Karl","year":"2014","journal-title":"Malar J"},{"key":"2022031508220895300_CIT0023","doi-asserted-by":"crossref","first-page":"4249","DOI":"10.1128\/AAC.04942-14","article-title":"Evaluating the pharmacodynamic effect of antimalarial drugs in clinical trials by quantitative PCR","volume":"59","author":"Marquart","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2022031508220895300_CIT0024","volume-title":"WHO handbook for reporting results of cancer treatment","author":"World Health Organization","year":"1979"},{"key":"2022031508220895300_CIT0025","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1172\/JCI98012","article-title":"A controlled human malaria infection model enabling evaluation of transmission-blocking interventions","volume":"128","author":"Collins","year":"2018","journal-title":"J Clin Invest"},{"key":"2022031508220895300_CIT0026","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1186\/s12936-018-2382-6","article-title":"Assessing Plasmodium falciparum transmission in mosquito-feeding assays using quantitative PCR","volume":"17","author":"Wang","year":"2018","journal-title":"Malar J"},{"key":"2022031508220895300_CIT0027","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1086\/513990","article-title":"Clinical manifestations of Plasmodium falciparum malaria experimentally induced by mosquito challenge","volume":"175","author":"Church","year":"1997","journal-title":"J Infect Dis"},{"key":"2022031508220895300_CIT0028","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1186\/s12936-016-1511-3","article-title":"A phase II pilot trial to evaluate safety and efficacy of ferroquine against early Plasmodium falciparum in an induced blood-stage malaria infection study","volume":"15","author":"McCarthy","year":"2016","journal-title":"Malar J"},{"key":"2022031508220895300_CIT0029","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.4269\/ajtmh.17-0754","article-title":"The dynamics of liver function test abnormalities after malaria infection: a retrospective observational study","volume":"98","author":"Woodford","year":"2018","journal-title":"Am J Trop Med Hyg"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiaa287\/33422288\/jiaa287.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/225\/6\/1062\/42897061\/jiaa287.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/225\/6\/1062\/42897061\/jiaa287.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,15]],"date-time":"2022-03-15T08:22:42Z","timestamp":1647332562000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/225\/6\/1062\/5849687"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,1]]},"references-count":29,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2020,6,1]]},"published-print":{"date-parts":[[2022,3,15]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiaa287","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,3,15]]},"published":{"date-parts":[[2020,6,1]]}}}